By analyzing the data sets from the cBioportal database (n = 4488), we found GSTM2 had a moderate mutation frequency in colon cancer patients (1%-4%), and about 50% of these mutations were deep deletion (Figure 4A). Here, GSTM2 is linked to malignant colon neoplasm.